EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Incorporating Individual‐Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations

Simon B Ascher iD, Richard L Kravitz iD, Rebecca Scherzer iD, Jarett D Berry iD, James A de Lemos iD, Michelle M Estrella iD, Daniel J Tancredi iD, Anthony A Killeen iD, Joachim H Ix iD, Michael G Shlipak iD

Journal of the American Heart Association · 20.08.2024 · 13 (16)

DOI: 10.1161/jaha.124.033995 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 20.08.2024. Verfasst von Simon B Ascher und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kidney Health Research Collaborative San Francisco Veterans Affairs Health Care System and University of California …. Hauptthemen laut MEDLINE: Antihypertensive Agents, Blood Pressure, Hypertension, Precision Medicine. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background There are no shared decision‐making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed whether results from the SPRINT (Systolic Blood Pressure Intervention Trial) could be tailored to individuals using predicted risks and simulated preferences. Methods and Results Among 8202 SPRINT participants, Cox models were developed and internally validated to predict each individual's absolute difference in risk from intensive versus standard BP lowering for cardiovascular events, cognitive impairment, death, and serious adverse events (AEs). Individual treatment effects were combined using simulated preference weights into a net benefit, which represents a weighted sum of risk differences across outcomes. Net benefits were compared among those above versus below the median AE risk. In simulations for which cardiovascular, cognitive, and death events had much greater weight than the AEs of BP lowering, the median net benefit was 3.3 percentage points (interquartile range [IQR], 2.0–5.7), and 100% of participants had a net benefit favoring intensive BP lowering. When simulating benefits and harms to have similar weights, the median net benefit was 0.8 percentage points (IQR, 0.2–2.2), and 87% had a positive net benefit. Compared with participants at lower risk of AEs from BP lowering, those at higher risk had a greater net benefit from intensive BP lowering despite experiencing more AEs ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsBlood PressureHypertensionPrecision MedicineHealth Planning GuidelinesAgedFemaleHumansMaleMiddle AgedDecision Making, SharedPatient PreferenceRisk AssessmentTreatment Outcome

Stichwörter der Autor:innen

hypertensionpatient preferencesprecision medicinepredictionshared decision‐making

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Kidney Health Research Collaborative San Francisco Veterans Affairs Health Care System and University of California San Francisco San Francisco CA.
  • Department of Internal Medicine University of California Davis Sacramento CA.
  • Department of Internal Medicine University of Texas at Tyler Health Science Center Tyler TX.
  • Division of Cardiology, Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX.
  • Department of Pediatrics University of California Davis Sacramento CA.
  • Department of Laboratory Medicine and Pathology University of Minnesota Minneapolis MN.

ORCID-Profile: Simon B Ascher, Richard L Kravitz, Rebecca Scherzer, Jarett D Berry, James A de Lemos, Michelle M Estrella, Daniel J Tancredi, Anthony A Killeen, Joachim H Ix, Michael G Shlipak

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NCRR NIH HHS
  • NHLBI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Ascher, S. B., Kravitz, R. L., Scherzer, R., Berry, J. D., de Lemos, J. A., Estrella, M. M., Tancredi, D. J., Killeen, A. A., Ix, J. H., & Shlipak, M. G. (2024). Incorporating Individual‐Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations. Journal of the American Heart Association, 13(16). https://doi.org/10.1161/jaha.124.033995

Vancouver

Ascher SB, Kravitz RL, Scherzer R, Berry JD, de Lemos JA, Estrella MM, et al. Incorporating Individual‐Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations. Journal of the American Heart Association. 2024;13(16). doi:10.1161/jaha.124.033995

BibTeX
@article{Ascher2024,
  author = {Ascher, Simon B and Kravitz, Richard L and Scherzer, Rebecca and Berry, Jarett D and de Lemos, James A and Estrella, Michelle M and Tancredi, Daniel J and Killeen, Anthony A and Ix, Joachim H and Shlipak, Michael G},
  title = {Incorporating Individual‐Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {16},
  doi = {10.1161/jaha.124.033995}
}
Kostenlos starten →